false --12-31 2026 Q3 0001661600 1 1 0001661600 2026-01-01 2026-09-30 0001661600 2026-11-16 0001661600 2026-09-30 0001661600 2025-12-31 0001661600 2026-07-01 2026-09-30 0001661600 2025-07-01 2025-09-30 0001661600 2025-01-01 2025-09-30 0001661600 us-gaap:CommonStockMember 2025-12-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001661600 us-gaap:RetainedEarningsMember 2025-12-31 0001661600 us-gaap:ParentMember 2025-12-31 0001661600 us-gaap:NoncontrollingInterestMember 2025-12-31 0001661600 us-gaap:CommonStockMember 2026-03-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001661600 us-gaap:RetainedEarningsMember 2026-03-31 0001661600 us-gaap:ParentMember 2026-03-31 0001661600 us-gaap:NoncontrollingInterestMember 2026-03-31 0001661600 2026-03-31 0001661600 us-gaap:CommonStockMember 2026-06-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001661600 us-gaap:RetainedEarningsMember 2026-06-30 0001661600 us-gaap:ParentMember 2026-06-30 0001661600 us-gaap:NoncontrollingInterestMember 2026-06-30 0001661600 2026-06-30 0001661600 us-gaap:CommonStockMember 2024-12-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001661600 us-gaap:RetainedEarningsMember 2024-12-31 0001661600 us-gaap:ParentMember 2024-12-31 0001661600 us-gaap:NoncontrollingInterestMember 2024-12-31 0001661600 2024-12-31 0001661600 us-gaap:CommonStockMember 2025-03-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001661600 us-gaap:RetainedEarningsMember 2025-03-31 0001661600 us-gaap:ParentMember 2025-03-31 0001661600 us-gaap:NoncontrollingInterestMember 2025-03-31 0001661600 2025-03-31 0001661600 us-gaap:CommonStockMember 2025-06-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001661600 us-gaap:RetainedEarningsMember 2025-06-30 0001661600 us-gaap:ParentMember 2025-06-30 0001661600 us-gaap:NoncontrollingInterestMember 2025-06-30 0001661600 2025-06-30 0001661600 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001661600 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001661600 us-gaap:ParentMember 2026-01-01 2026-03-31 0001661600 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001661600 2026-01-01 2026-03-31 0001661600 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001661600 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001661600 us-gaap:ParentMember 2026-04-01 2026-06-30 0001661600 us-gaap:NoncontrollingInterestMember 2026-04-01 2026-06-30 0001661600 2026-04-01 2026-06-30 0001661600 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001661600 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001661600 us-gaap:ParentMember 2026-07-01 2026-09-30 0001661600 us-gaap:NoncontrollingInterestMember 2026-07-01 2026-09-30 0001661600 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001661600 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001661600 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001661600 us-gaap:ParentMember 2025-01-01 2025-03-31 0001661600 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001661600 2025-01-01 2025-03-31 0001661600 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001661600 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001661600 us-gaap:ParentMember 2025-04-01 2025-06-30 0001661600 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001661600 2025-04-01 2025-06-30 0001661600 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001661600 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001661600 us-gaap:ParentMember 2025-07-01 2025-09-30 0001661600 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001661600 us-gaap:CommonStockMember 2026-09-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001661600 us-gaap:RetainedEarningsMember 2026-09-30 0001661600 us-gaap:ParentMember 2026-09-30 0001661600 us-gaap:NoncontrollingInterestMember 2026-09-30 0001661600 us-gaap:CommonStockMember 2025-09-30 0001661600 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001661600 us-gaap:RetainedEarningsMember 2025-09-30 0001661600 us-gaap:ParentMember 2025-09-30 0001661600 us-gaap:NoncontrollingInterestMember 2025-09-30 0001661600 2025-09-30 0001661600 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember satt:ConvertibleComponentMember 2026-09-30 0001661600 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember satt:ConvertibleComponentMember 2026-09-30 0001661600 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember satt:ConvertibleComponentMember 2026-09-30 0001661600 us-gaap:FairValueMeasurementsRecurringMember satt:ConvertibleComponentMember 2026-09-30 0001661600 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001661600 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001661600 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001661600 us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001661600 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember satt:ConvertibleComponentMember 2025-12-31 0001661600 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember satt:ConvertibleComponentMember 2025-12-31 0001661600 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember satt:ConvertibleComponentMember 2025-12-31 0001661600 us-gaap:FairValueMeasurementsRecurringMember satt:ConvertibleComponentMember 2025-12-31 0001661600 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001661600 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001661600 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001661600 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001661600 satt:February2019LoanMember 2019-02-21 0001661600 satt:February2019LoanMember 2026-09-30 0001661600 satt:February2019LoanMember 2025-12-31 0001661600 satt:February2019LoanMember 2026-01-01 2026-09-30 0001661600 satt:February2019LoanMember 2025-01-01 2025-12-31 0001661600 satt:October2019LoanMember 2019-10-15 0001661600 satt:October2019LenderMember 2022-01-25 2022-01-26 0001661600 satt:October2019LenderMember 2022-12-19 2022-12-20 0001661600 satt:October2019LenderMember 2023-01-01 2023-01-31 0001661600 satt:October2019LenderMember 2026-09-30 0001661600 satt:October2019LenderMember 2025-12-31 0001661600 satt:October2019LenderMember 2026-01-01 2026-09-30 0001661600 satt:October2019LenderMember 2025-01-01 2025-12-31 0001661600 satt:August2020LoanMember 2020-08-07 0001661600 satt:August2020LenderMember 2026-09-30 0001661600 satt:August2020LenderMember 2025-12-31 0001661600 satt:August2020LoanMember us-gaap:WarrantMember 2020-08-07 0001661600 satt:August2020LoanMember 2026-01-01 2026-09-30 0001661600 satt:August2020LoanMember 2025-01-01 2025-12-31 0001661600 satt:July2020DirectorLoanMember 2020-07-31 0001661600 satt:July2020DirectorLoanMember 2020-07-30 2020-07-31 0001661600 satt:DirectorLoanMember 2026-09-30 0001661600 satt:DirectorLoanMember 2025-12-31 0001661600 satt:July2020DirectorLoanMember 2026-01-01 2026-09-30 0001661600 satt:July2020DirectorLoanMember 2025-10-01 2025-12-31 0001661600 satt:March2025LoanMember 2024-03-31 0001661600 us-gaap:WarrantMember satt:February2019LoanMember 2026-01-01 2026-09-30 0001661600 satt:WarrantsMember satt:October2019LoanMember 2026-01-01 2026-09-30 0001661600 us-gaap:WarrantMember satt:August2020LoanMember 2026-01-01 2026-09-30 0001661600 us-gaap:WarrantMember satt:August72020LoanMember 2026-01-01 2026-09-30 0001661600 satt:July312020LoanMember 2026-01-01 2026-09-30 0001661600 satt:WarrantsMember satt:July312020LoanMember 2026-01-01 2026-09-30 0001661600 us-gaap:MeasurementInputSharePriceMember satt:February2019LoanMember 2025-01-01 2025-12-31 0001661600 satt:MeasurementInputWeightedAverageSharePriceMember satt:February2019LoanMember 2025-01-01 2025-12-31 0001661600 us-gaap:MeasurementInputSharePriceMember satt:February2019LoanMember 2026-01-01 2026-09-30 0001661600 satt:MeasurementInputWeightedAverageSharePriceMember satt:February2019LoanMember 2026-01-01 2026-09-30 0001661600 us-gaap:MeasurementInputSharePriceMember satt:October2019LoanMember 2025-01-01 2025-12-31 0001661600 satt:MeasurementInputWeightedAverageSharePriceMember satt:October2019LoanMember 2025-01-01 2025-12-31 0001661600 us-gaap:MeasurementInputSharePriceMember satt:October2019LoanMember 2026-01-01 2026-09-30 0001661600 satt:MeasurementInputWeightedAverageSharePriceMember satt:October2019LoanMember 2026-01-01 2026-09-30 0001661600 satt:August2020LoanMember satt:BlackScholesMertonMember us-gaap:MeasurementInputSharePriceMember 2020-08-01 2020-08-31 0001661600 satt:August2020LoanMember satt:BlackScholesMertonMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-08-01 2020-08-31 0001661600 satt:August2020LoanMember satt:BlackScholesMertonMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-08-01 2020-08-31 0001661600 satt:August2020LoanMember satt:BlackScholesMertonMember us-gaap:MeasurementInputExpectedTermMember 2020-08-01 2020-08-31 0001661600 satt:August2020LoanMember satt:BlackScholesMertonMember us-gaap:MeasurementInputPriceVolatilityMember 2020-08-01 2020-08-31 0001661600 satt:August2020LoanMember satt:MonteCarloMember us-gaap:MeasurementInputSharePriceMember 2020-08-06 2020-08-07 0001661600 satt:August2020LoanMember satt:MonteCarloMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-08-06 2020-08-07 0001661600 satt:August2020LoanMember satt:MonteCarloMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-08-06 2020-08-07 0001661600 satt:August2020LoanMember satt:MonteCarloMember us-gaap:MeasurementInputExpectedTermMember 2020-08-06 2020-08-07 0001661600 satt:August2020LoanMember satt:MonteCarloMember us-gaap:MeasurementInputPriceVolatilityMember 2020-08-06 2020-08-07 0001661600 satt:August2020LoanMember us-gaap:MeasurementInputSharePriceMember 2025-01-01 2025-12-31 0001661600 satt:August2020LoanMember satt:MeasurementInputWeightedAverageSharePriceMember 2025-01-01 2025-12-31 0001661600 satt:August2020LoanMember us-gaap:MeasurementInputSharePriceMember 2026-01-01 2026-09-30 0001661600 satt:August2020LoanMember satt:MeasurementInputWeightedAverageSharePriceMember 2026-01-01 2026-09-30 0001661600 us-gaap:MeasurementInputSharePriceMember satt:July2020DirectorLoanMember satt:July2020WarrantsMember 2020-08-01 2020-08-31 0001661600 us-gaap:MeasurementInputExpectedDividendRateMember satt:July2020DirectorLoanMember satt:July2020WarrantsMember 2020-08-01 2020-08-31 0001661600 us-gaap:MeasurementInputRiskFreeInterestRateMember satt:July2020DirectorLoanMember satt:July2020WarrantsMember 2020-08-01 2020-08-31 0001661600 us-gaap:MeasurementInputExpectedTermMember satt:July2020DirectorLoanMember satt:July2020WarrantsMember 2020-08-01 2020-08-31 0001661600 us-gaap:MeasurementInputPriceVolatilityMember satt:July2020DirectorLoanMember satt:July2020WarrantsMember 2020-08-01 2020-08-31 0001661600 us-gaap:MeasurementInputSharePriceMember satt:July2020DirectorLoanMember satt:BeneficialConversionFeatureMember 2025-01-01 2025-12-31 0001661600 satt:MeasurementInputWeightedAverageSharePriceMember satt:July2020DirectorLoanMember satt:BeneficialConversionFeatureMember 2025-01-01 2025-12-31 0001661600 us-gaap:MeasurementInputSharePriceMember satt:July2020DirectorLoanMember satt:BeneficialConversionFeatureMember 2026-01-01 2026-09-30 0001661600 satt:MeasurementInputWeightedAverageSharePriceMember satt:July2020DirectorLoanMember satt:BeneficialConversionFeatureMember 2026-01-01 2026-09-30 0001661600 srt:ChiefFinancialOfficerMember 2026-01-01 2026-09-30 0001661600 srt:ChiefFinancialOfficerMember 2026-09-30 0001661600 satt:CompanyControlledByCfoMember 2026-01-01 2026-09-30 0001661600 satt:CompanyControlledByCfoMember 2026-09-30 0001661600 satt:DirectorAndCeoMember 2026-01-01 2026-09-30 0001661600 satt:DirectorAndCeoMember 2026-09-30 0001661600 satt:DirectorsMember 2026-01-01 2026-09-30 0001661600 satt:DirectorsMember 2026-09-30 0001661600 satt:AllRelatedPartiesMember 2026-01-01 2026-09-30 0001661600 satt:AllRelatedPartiesMember 2026-09-30 0001661600 srt:ChiefFinancialOfficerMember 2025-01-01 2025-09-30 0001661600 srt:ChiefFinancialOfficerMember 2025-09-30 0001661600 satt:CompanyControlledByCfoMember 2025-01-01 2025-09-30 0001661600 satt:CompanyControlledByCfoMember 2025-09-30 0001661600 satt:DirectorsMember 2025-01-01 2025-09-30 0001661600 satt:DirectorsMember 2025-09-30 0001661600 satt:AllRelatedPartiesMember 2025-01-01 2025-09-30 0001661600 satt:AllRelatedPartiesMember 2025-09-30 0001661600 satt:FormerCEOMember 2026-01-01 2026-09-30 0001661600 us-gaap:WarrantMember 2024-12-31 0001661600 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001661600 us-gaap:WarrantMember 2025-12-31 0001661600 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001661600 us-gaap:WarrantMember 2026-09-30 0001661600 2025-01-01 2025-12-31 0001661600 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001661600 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-12-31 0001661600 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001661600 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001661600 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001661600 satt:FinancialIncomeExpenseMember 2026-07-01 2026-09-30 0001661600 satt:FinancialIncomeExpenseMember 2025-07-01 2025-09-30 0001661600 satt:FinancialIncomeExpenseMember 2026-01-01 2026-09-30 0001661600 satt:FinancialIncomeExpenseMember 2025-01-01 2025-09-30 0001661600 satt:ForeignCurrencyTransactionsAndOtherMember 2026-07-01 2026-09-30 0001661600 satt:ForeignCurrencyTransactionsAndOtherMember 2025-07-01 2025-09-30 0001661600 satt:ForeignCurrencyTransactionsAndOtherMember 2026-01-01 2026-09-30 0001661600 satt:ForeignCurrencyTransactionsAndOtherMember 2025-01-01 2025-09-30 0001661600 satt:SaffronTechMember 2026-01-01 2026-09-30 0001661600 satt:SaffronTechMember 2025-09-28 2025-09-29 0001661600 satt:BioHarvestMember 2025-09-28 2025-09-29 0001661600 satt:SaffronTechMember satt:PhaseIMember 2025-09-29 0001661600 satt:SaffronTechMember satt:PhaseIIMember 2025-09-29 0001661600 satt:SaffronTechMember satt:PhaseIIIMember 2025-09-29 0001661600 satt:BioHarvestMember 2025-01-01 2025-12-31 0001661600 satt:BioHarvestMember satt:PhaseIMember 2025-09-29 0001661600 satt:BioHarvestMember satt:PhaseIIMember 2025-09-29 0001661600 satt:BioHarvestMember satt:PhaseIIIMember 2025-09-29 0001661600 satt:BioHarvestMember 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure satt:Integer

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

for the quarterly period ended September 30, 2026

 

OR

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the period from                to               .

 

Commission file number: 333-208814

 

SATIVUS TECH CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   47-2847446
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     

#3 Bethesda Metro Center, #700

Bethesda, MD

  20814
(Address of principal executive offices)   (Zip Code)

 

800 608-6432

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
NA   NA   NA

 

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ☒

 

As of November 16, 2026, the registrant had 4,215,571 shares of its Common Stock, $0.0001 par value, outstanding.

 

When used in this quarterly report, the terms “Sativus Tech Corp.,” “the Company,” “we,” “our,” and “us” refer to Sativus Tech Corp.

 

 

   

 

 

TABLE OF CONTENTS

 

 

PART I. FINANCIAL INFORMATION 3
     
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 3
     
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 25
     
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 30
     
ITEM 4. CONTROLS AND PROCEDURES 30
     
PART II OTHER INFORMATION 32
     
ITEM 5. OTHER INFORMATION 32
     
ITEM 6. EXHIBITS 32
     
SIGNATURES 33

 

 

 

 

 

 

 

 

 

 2 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Financial Statements

 

SATIVUS TECH CORP.

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of September 30, 2026

 

IN THOUSANDS OF U.S. DOLLARS

 

INDEX

 

  Page
   
Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025 4
   
Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2026 (unaudited) and 2025 5
   
Condensed Consolidated Statements of Changes in Shareholders’ Deficit for the Nine Months Ended September 30, 2026 (unaudited) and 2025 (unaudited) 6
   
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 (unaudited) and 2025 (unaudited) 7
   
Notes to Condensed Consolidated Financial Statements (Unaudited) 8

 

 

 

 

 

 

 

 

 

 

 3 

 

 

SATIVUS TECH CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands, except share and per share data

 

         
   September 30,   December 31, 
   2026   2025 
   (Unaudited)   (Audited) 
ASSETS          
           
CURRENT ASSETS:          
Cash and cash equivalents  $18   $32 
Restricted cash   10    9 
Accounts receivable   –    21 
Prepaid expenses and other receivables   13    41 
Total current assets   41    103 
           
NON-CURRENT ASSETS          
Property and equipment, net   144    204 
Total non-current assets   144    204 
           
Total assets  $185   $307 
           
LIABILITIES AND SHAREHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES          
Accounts payable  $293   $267 
Convertible loans   2,577    2,451 
Loans from related party   122    98 
Fair value of convertible component in convertible loans   757    726 
Other accounts payable   306    296 
Total current liabilities   4,055    3,838 
           
SHAREHOLDERS’ DEFICIT          
Ordinary shares of $0.0001 par value Authorized: 500,000,000 shares at September 30, 2026 and December 31, 2025; Issued and Outstanding: 4,215,571 and 4,215,571 shares at September 30, 2026 and December 31, 2025, respectively   4    4 
Additional paid-in capital   21,083    20,973 
Accumulated deficit   (24,881)   (24,477)
Shareholders’ deficit   (3,794)   (3,500)
Non-controlling interests   (76)   (31)
Total shareholders’ deficit   (3,870)   (3,531)
           
Total liabilities and shareholders’ deficit  $185   $307 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 4 

 

 

SATIVUS TECH CORP.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)

U.S. dollars in thousands, except share and per share data

 

                 
   Three months ended   Nine months ended 
   September 30,
2026
   September 30,
2025
   September 30,
2026
   September 30,
2025
 
Operating expenses:                    
Research and development  $(15)  $(169)  $(187)  $(497)
                     
General and administrative   (51)   (151)   (185)   (296)
                     
Operating loss   (66)   (320)   (372)   (793)
                     
Financial income (expenses), net   (179)   (83)   (167)   (130)
                     
Net loss   (245)   (403)   (539)   (923)
                     
Non-controlling interests   (16)   (137)   (135)   (324)
Net loss attributable to equity holders of the Company  $(229)  $(266)  $(404)  $(599)
                     
Basic and diluted net loss per share  $(0.05)  $(0.05)  $(0.10)  $(0.14)
                     
Weighted average number of Ordinary shares used in computing basic and diluted loss per share   4,215,571    4,215,571    4,215,571    4,215,571 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 

 

 

 

 5 

 

 

SATIVUS TECH CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

U.S. dollars in thousands, except share and per share data

 

 

Nine months ended September 30, 2026:

                             
   Ordinary shares   Additional paid-in   Accumulated   Total Shareholders’   Non-
controlling
     
   Number   Amount   Capital   Deficit   Deficit   Interests   Total 
Balance as of January 1, 2026   4,215,571   $4   $20,973   $(24,477)  $(3,500)  $(31)  $(3,531)
                                    
Net income (loss)   –    –    –    (195)   (195)   (57)   (252)
Balance as of March 31, 2026 (Unaudited)   4,215,571    4    20,973    (24,672)   (3,695)   (88)   (3,783)
Investment in subsidiary through SAFE agreements   –    –    110    –    110    90    200 
                                    
Net income (loss)   –    –    –    20    20    (62)   (42)
Balance as of June 30, 2026 (Unaudited)   4,215,571    4    21,083    (24,652)   (3,565)   (60)   (3,625)
                                    
Net income (loss)   –    –    –    (229)   (229)   (16)   (245)
Balance as of September 30, 2026 (Unaudited)   4,215,571   $4   $21,083   $(24,881)  $(3,794)  $(76)  $(3,870)

 

Nine months ended September 30, 2025 (comparative):

                             
   Ordinary shares   Additional paid-in   Accumulated   Total Shareholders’   Non-
controlling
     
   Number   Amount   Capital   Deficit   Deficit   Interests   Total 
Balance as of January 1, 2025   4,215,571   $4   $20,683   $(23,608)  $(2,921)  $251   $(2,670)
Issuance of shares in respect of converted SAFE in subsidiary   –    –    11    –    11    7    18 
                                    
Net income (loss)   –    –    –    (1)   (1)   (97)   (98)
Balance as of March 31, 2025 (Unaudited)   4,215,571    4    20,694    (23,609)   (2,911)   161    (2,750)
Issuance of shares in respect of converted SAFE in subsidiary   –    –    11    –    11    9    20 
                                    
Net income (loss)   –    –    –    (332)   (332)   (90)   (422)
Balance as of June 30, 2025 (Unaudited)   4,215,571    4    20,705    (23,941)   (3,232)   80    (3,152)
Issuance of shares in subsidiary   –    –    268    –    268    198    466 
                                    
Net income (loss)   –    –    –    (266)   (266)   (137)   (403)
Balance as of September 30, 2025 (Unaudited)   4,215,571   $4   $20,973   $(24,207)  $(3,230)  $141   $(3,089)

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 6 

 

 

SATIVUS TECH CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

U.S. dollars in thousands

 

         
   Nine months ended 
   September 30, 
   2026   2025 
Cash flows from operating activities:          
Net income (loss)  $(539)  $(923)
Adjustments to reconcile loss to net cash used in operating activities:          
Depreciation and amortization   60    89 
Share based compensation expenses to employees and non-employees   –    – 
Financial expenses related to convertible loans and warrants   126    127 
Change in fair value of convertible component in convertible loans   31    (48)
           
Changes in assets and liabilities:          
Decrease (increase) in other accounts receivable   28    (22)
Decrease (increase) in accounts receivable   21    (20)
Increase (decrease) in trade payables   26    207 
Increase (decrease) in other accounts payable   10    108 
Net cash used in operating activities   (237)   (482)
           
Cash flows from investing activities:          
Decrease (increase) in restricted cash   (1)   5 
Net cash provided by investing activities   (1)   5 
           
Cash flows from financing activities:          
Proceeds from loans from related party   24    – 
Proceeds from convertible loans   –    36 
Proceeds from issuance of shares and SAFE agreements in subsidiary   200    504 
Net cash provided by financing activities   224    540 
           
Increase (decrease) in cash and cash equivalents   (14)   63 
Cash and cash equivalents at the beginning of the year   32    96 
Cash and cash equivalents at the end of the period  $18   $159 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 7 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 1: GENERAL

 

  a. SATIVUS TECH CORP. (formerly SEEDO CORP.) (the “Company”, “Our” or “We”) was formed on January 16, 2015, under the laws of the State of Delaware. Prior to July 2020, we were involved in producing a plant growing device managed and controlled by an artificial intelligence algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant, while providing optimal conditions to assure premium quality produce year-round. However, due to financial and operational difficulties and during 2020, we ceased these operations and on July 19, 2020, the Company formed a new wholly-owned subsidiary in Israel, Hachevra Legiduley Pkaot Beisrael Ltd. (the “New Subsidiary”), to develop a fully automated and remotely managed system for growing saffron and other vegetables. On November 5, 2020, the New Subsidiary changed its name to Saffron-Tech Ltd. (or “Saffron Tech”). As of the date of this report, and following various financings in Saffron Tech, the Company owns 54% of Saffron Tech.
     
   

The Company, through Saffron Tech, is focusing on its in-house research and development of agriculture technology products, among others, in the fields of exotic plants and mushrooms. Saffron Tech plans to roll out its proof of concept in the coming months. This technology will provide turnkey automated growing containers for high-quality, high-yield saffron all year round. The Company is in advanced stages of developing and testing a fully automated and remotely managed system for growing high-quality, high-yield saffron anywhere and anytime.

 

It is also environmentally friendly, using economic levels of water, space, fertilizer, and energy. According to the Company’s calculations, we believe that the controlled indoor growing area will produce ten times more yield compared to the same land area using traditional methods. The sealed environment eliminates the need for harmful pesticides and herbicides, producing a clean and safe product that is easy to control from anywhere. The Company’s solution is easily scalable and pre-designed to quickly grow operations.

 

Saffron is used in many industries, such as the food industry, particularly by famous chefs and Michelin starred restaurants, the natural cosmetics industry and the food supplements industry and as a dye in the textile industry. Medicinal claims as an anti-depressant, antioxidant, and antiseptic are constantly increasing.

 

  b. The Company has an accumulated deficit in the total amount of $24,881 as of September 30, 2026; the Company has negative operating cash flow in the total amount of $237 for the nine months ended September 30, 2026; and further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.
     
    The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, and future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company requires more funds than anticipated during the next 12 months or in later periods.

 

 

 

 8 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 1: GENERAL (cont.)

 

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.

 

The consolidated financial statements for the nine months ended September 30, 2026, do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

 

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation:

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its 54%-owned subsidiary and were prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”)

 

All intercompany accounts and transactions have been eliminated in the consolidation.

 

Unaudited Interim Financial Information

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2025, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 15th, 2026 (the “2025 Annual Report”). The results for any interim period are not necessarily indicative of results for any future period.

 

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the nine months ended September 30, 2026, are not necessarily indicative of the results for the year ending December 31, 2026, or for any future period.

 

As of September 30, 2026, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2025 Annual Report.

 

 

 

 9 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Fair value of financial instruments

 

ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

 

In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  Level 1 — Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.
     
  Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
     
  Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The carrying amounts of cash and cash equivalents, short term deposits, trade receivables, trade payables and short-term loans approximate their fair value due to the short-term maturity of such instruments.

 

The Company elected to measure some of the convertible loans under the fair value option. Under the fair value option the convertible loans will be measured at fair value in each reporting period until they will be converted, with changes in the fair values being recognized in the Company’s consolidated statement of operations as financial income or expense. The proceeds received for the issuance of the convertible loans were allocated at fair value conducted on an arm’s-length basis.

 

 

 

 10 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

The Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:

                
   Balance as of September 30, 2026 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loans, net of discounts and debt issue costs  $–   $–   $757   $757 
                     
Total liabilities  $–   $–   $757   $757 

 

   Balance as of December 31, 2025 
   Level 1   Level 2   Level 3   Total 
Liabilities:                
Fair Value of convertible component in convertible loans, net of discounts and debt issue costs  $–   $–   $726   $726 
                     
Total liabilities  $–   $–   $726   $726 

 

Segment Reporting

 

ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s business is comprised of one operating segment.

 

NOTE 3: CONVERTIBLE LOANS

 

  a. On February 21, 2019, the Company received a convertible loan from a third party (“February 2019 Lender”), with a two-year term, in the principal amount of $550, which bears a 10% annual interest rate (“February 2019 Loan”).

 

 

 

 11 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 3: CONVERTIBLE LOANS (cont.)

 

The Company, at its option, shall have the right to redeem, in part or in whole, the outstanding principal amount and interest under this loan agreement prior to the maturity date. The Company shall pay an amount equal to the principal amount being redeemed plus a redemption premium equal to 20% of the outstanding principal amount being redeemed plus outstanding and accrued interest.

 

The February 2019 Lender shall be entitled to convert at its option any portion of the outstanding and unpaid principal or accrued interest into fully paid and non-assessable shares of common stock, at the lower of the fixed conversion price then in effect or the market conversion price. The number of shares of common stock issuable upon conversion of any conversion amount shall be determined by dividing (x) such conversion amount by (y) the fixed conversion price of $20.00 or (z) 80% of the lowest volume-weighted average price of the Company’s shares of common stock during the 30 trading days immediately preceding the conversion date.

 

On July 31, 2026, the loan agreement was extended until March 31, 2027.

 

The February 2019 Loan is included in the convertible loans in current liabilities as of September 30, 2026, in the amount of $442, and $422 as of December 31, 2025.

 

The Company accounted for the February 2019 Loan in accordance with ASC 470-20, Debt with conversion and other Options. The value of the BCF for the February 2019 Loan was calculated using Monte Carlo model. As of September 30, 2026 the Company allocated $238 to the BCF as a liability ($200 as of December 31, 2025).

 

As of December 31, 2025 the fair value of the conversion feature in the amount of $200 was calculated with the following parameters:

    
   December 31,
2025
 
Share price  $0.12 
80% of the lowest volume-weighted average price  $0.096 

 

 

 

 12 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 3: CONVERTIBLE LOANS (cont.)

 

As of September 30, 2026 the fair value of the conversion feature in the amount of $238 was calculated with the following parameters:

     
   September 30,
2026
 
Share price  $0.186 
80% of the lowest volume-weighted average price  $0.121 

 

During the nine months ended September 30, 2026 the Company recorded interest expenses related to the Loan in the amount of $20.

 

  b. On October 15, 2019, the Company received a convertible loan from a third party (“October 2019 Lender”) in the principal amount of $1,100 that bears an annual 10% interest rate (“October 2019 Loan”). The October 2019 Loan had a two-year term. Prior to the maturity date of the October 2019 Loan, the Company, at its option, has the right to redeem, in cash, in part or in whole, the amounts outstanding provided that as of the date of the redemption notice (i) the volume-weighted average price of the Company’s ordinary shares is less than $12.50 and (ii) there are no equity condition failures as defined therein. In the event that the Company wishes to redeem any amount under the convertible loan, the Company shall pay an amount equal to the principal amount being redeemed plus a redemption premium equal to 20% of the outstanding amount being redeemed in addition to outstanding and accrued interest.

 

The October 2019 Lender shall be entitled to convert the principal loan and the outstanding interest (the “Conversion Amount”) into such number of ordinary shares determined by dividing (x) such Conversion Amount by (y) the fixed conversion price of $12.50 or (z) 80% of the lowest volume-weighted average price of the Company’s ordinary shares during the 10 trading days immediately preceding the conversion date.

 

On January 26, 2022, the Company paid accrued interest of the October 2019 Loan in the amount of $55.

 

On December 20, 2022, the Company paid accrued interest of the October 2019 Loan in the amount of $100, and the October 2019 Loan agreement was extended until June 30, 2023.

 

In January 2023, the Company paid accrued interest of the October 2019 Loan in the amount of $100.

 

On July 31, 2026, the loan agreement was extended until March 31, 2027.

 

 

 

 13 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 3: CONVERTIBLE LOANS (cont.)

 

The October 2019 Loan is included in the convertible loans in current liabilities as of September 30, 2026, in the amount of $1,611 and $1,528 as of December 31, 2025.

 

The Company accounted for the October 2019 Loan in accordance with ASC 470-20, Debt with conversion and other Options. The value of the BCF for the October 2019 Loan was calculated using Monte Carlo model. As of September 30, 2026 the Company allocated $403 to the BCF as a liability ($408 as of December 31, 2025).

 

As of December 31, 2025 the fair value of the conversion feature in the amount of $408 was calculated with the following parameters:

    
   December 31,
2025
 
Share price  $0.14 
80% of the lowest volume-weighted average price  $0.112 

 

As of September 30, 2026 the fair value of the conversion feature in the amount of $403 was calculated with the following parameters:

     
   September 30,
2026
 
Share price  $0.186 
80% of the lowest volume-weighted average price  $0.149 

 

During the nine months ended September 30, 2026 the Company recorded interest expenses related to the Loan in the amount of $83.

 

  c. On August 7, 2020, the Company received a convertible loan from a third party (“August 2020 Lender”) in the amount of $200 (the “August 2020 Loan”). Per the terms of the Agreement, the August 2020 Loan has a maturity date of August 7, 2022 (“Maturity Date”) and accrues annual interest at a rate of 10%.

 

The August 2020 Loan is convertible by the August 2020 Lender into Shares, at their discretion, at the lower of a fixed price of $1.02 (the “Fixed Conversion Price”) or 80% of the lowest volume weighted average price (“VWAP”) of the Company’s common stock during the 10 trading days immediately preceding the conversion date (the “Market Conversion Price”).

 

On July 31, 2026, the loan agreement was extended until March 31, 2027.

 

 

 

 14 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 3: CONVERTIBLE LOANS (cont.)

 

The August 2020 Loan is included in the convertible loans in current liabilities as of September 30, 2026, in the amount of $323 and $308 as of December 31, 2025.

 

The Company also granted the August 2020 Lender warrants to purchase 50,000 shares of common stock of the Company at an exercise price of $2.00 per share, such exercise price is subject to any future price-based anti-dilution adjustments. In accordance with ASU 2017-11 the warrants were classified in shareholders’ equity.

 

The fair value of the warrants granted was $35 using the Black-Scholes-Merton option pricing model using the following assumptions:

    
   August
2020
 
Share price  $0.86 
Dividend yield   0% 
Risk-free interest rate   0.21% 
Expected term (in years)   5 
Volatility   176.96% 

 

The Company accounted for the August 2020 Loan in accordance with ASC 470-20, Debt with conversion and other Options. The combined intrinsic value of the BCF for the August 2020 Loan was calculated and valued at $249 as of August 7, 2020, and the Company allocated $58 to the BCF as a liability. As of September 30, 2026, the BCF was revalued at $81 ($83 as of December 31, 2025).

 

As of August 7, 2020, the Company used an independent appraiser to estimate the fair value of BCF which used the Monte Carlo option pricing model using the following weighted average assumptions:

    
   August 7,
2020
 
Share price  $0.80 
Dividend yield   0% 
Risk-free interest rate   0.13% 
Expected term (in years)   2 
Volatility   163.31% 

 

 

 

 15 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 3: CONVERTIBLE LOANS (cont.)

 

As of December 31, 2025 the fair value of the conversion feature in the amount of $83 was calculated with the following parameters:

 

   December 31,
2025
 
Share price  $0.14 
80% of the lowest volume-weighted average price  $0.112 

 

As of September 30, 2026 the fair value of the conversion feature in the amount of $81 was calculated with the following parameters:

 

   September 30,
2026
 
Share price  $0.186 
80% of the lowest volume-weighted average price  $0.149 

  

During the nine months ended September 30, 2026 the Company recorded interest expenses related to the Loan in the amount of $15.

 

  d. On July 31, 2020, the Company received a convertible loan from Mr. Shmuel Yannay (a third party at that time, and a director of the Company from October 28, 2021 until October 20, 2025) in the amount of $100 (“Director Loan”). The loan has a maturity date of July 31, 2022 (“Maturity Date”) and accrues annual interest at a rate of 10%.

 

The Director Loan is convertible into Shares, at his discretion, at the lower of a fixed price of $1.02 (the “Fixed Conversion Price”) or 80% of the lowest volume weighted average price (“VWAP”) of the Company’s common stock during the 10 trading days immediately preceding the conversion date (the “Market Conversion Price”).

 

The Company also granted Mr. Yannay warrants to purchase 25,000 shares of common stock of the Company at an exercise price of $2.00 per share, such exercise price is subject to any future price-based anti-dilution adjustments. In accordance with ASU 2017-11 the warrants were classified in shareholders’ equity.

 

 

 

 16 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 3: CONVERTIBLE LOANS (cont.)

 

The fair value of the warrants granted was $18 using the Black-Scholes-Merton option pricing model using the following assumptions:

    
   August
2020
 
Share price  $0.86 
Dividend yield   0% 
Risk-free interest rate   0.21% 
Expected term (in years)   5 
Volatility   176.96% 

 

On July 31, 2026, the loan agreement was extended until March 31, 2027.

 

The Director Loan is included in the convertible loans in current liabilities as of September 30, 2026, in the amount of $140 and $132 as of December 31, 2025.

 

The Company accounted for the director’s loan in accordance with ASC 470-20, Debt with conversion and other Options. The combined intrinsic value of the BCF for the Director Loan was calculated and valued at $129 as of July 31, 2020, and the Company allocated $129 to the BCF as a liability. As of September 30, 2026, the BCF was revalued at $35 ($35 as of December 31, 2025).

 

As of December 31, 2025 the fair value of the conversion feature in the amount of $35 was calculated with the following parameters:

    
   December 31,
2025
 
Share price  $0.14 
80% of the lowest volume-weighted average price  $0.112 

 

As of September 30, 2026 the fair value of the conversion feature in the amount of $35 was calculated with the following parameters:

     
   September 30,
2026
 
Share price  $0.186 
80% of the lowest volume-weighted average price  $0.149 

 

 

 

 17 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 3: CONVERTIBLE LOANS (cont.)

 

During the nine months ended September 30, 2026, the Company recorded interest expenses related to Director Loan in the amount of $8.

 

  e. In March 2025, the Company received a $36 convertible loan from a third party. The loan is convertible at a conversion ratio of $1 per share.

 

  f. On July 31, 2026, the Company entered into a further forbearance and extension agreement, and a corresponding amended and restated repayment agreement, with YA II PN, Ltd. (“YAII”) with respect to the Company's outstanding convertible debentures. Under the agreement, YAII agreed to extend the forbearance period through March 31, 2027.

 

 

NOTE 4: RELATED PARTIES

 

The following transactions arose with related parties:

                    
   Nine months ended September 30, 2026   Amounts owing 
   Directors
Fees
   Consulting
Fees / Salaries
   Interests   Total   by (to) as of
September 30,
2026
 
CFO  $–   $26   $–   $26   $(7)
Company controlled by CFO   –    25    –    25    (2)
Director and CEO   –    54    –    54    (149)
Directors   –    –    8    8    (363)
   $–   $105   $8   $113   $(521)

 

 

 

 

 18 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 4: RELATED PARTIES (cont.)

 

   Nine months ended September 30, 2025   Amounts owing 
   Directors
Fees
   Consulting
Fees / Salaries
  

Other

Expenses

   Total   by (to) as of
September 30,
2025
 
CFO  $–   $24   $–   $24   $– 
Company controlled by CFO   –    25    –    25    (24)
Directors   –    –    8    8    (130)
   $–   $49   $8   $57   $(154)

 

  A. The Company signed an agreement with the CFO, effective December 1, 2023, pursuant to which the CFO received $3 per month for his services. Amounts owed to the CFO as of September 30, 2026, were $7.
     
  B. The Company signed an agreement with the new CEO of the Company, effective October 20, 2025, pursuant to which the Company paid consulting fees to the CEO of NIS 54 thousand per month for the nine months ended September 30, 2026. Amounts owed to the CEO as of September 30, 2026, were $149.

 

 

NOTE 5: SHAREHOLDERS’ DEFICIT

 

  a. As of September 30, 2026 and December 31, 2025, the Company’s share capital is composed as follows:

                    
   September 30,
2026
   December 31,
2025
 
   Authorized   Issued and
outstanding
   Authorized   Issued and
outstanding
 
   Number of shares 
Shares of common stock of $0.0001 par value each “Shares”   500,000,000    4,215,571    500,000,000    4,215,571 

 

Each Ordinary share is entitled to receive dividend, participate in the distribution of the Company’s net assets upon liquidation and to receive notices of, participate in and vote (at one vote per share) at the general meetings of the Company on any matter upon which the general meeting is authorized.

 

 

 

 19 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 5: SHAREHOLDERS’ DEFICIT (cont.)

 

On December 9, 2021, we implemented a 1-for-10 consolidation, or reverse split, of our issued and outstanding common shares. Except where otherwise indicated, all share and per share data in these financial statements have been retroactively restated to reflect the reverse stock split.

 

  b. Warrants
     
    A summary of warrant activity during the nine-month period ended September 30, 2026, and year ended December 31, 2025 is as follows:

          
   Number   Average
exercise
price
 
Warrants outstanding at January 1, 2025   75,000   $2 
Expired   (75,000)   2 
Warrants outstanding at December 31, 2025   –    – 
Expired   –    – 
Warrants outstanding at September 30, 2026   –   $– 

 

    There were no warrants outstanding as of September 30, 2026 and December 31, 2025.
     
  c. Share option plans:
     
   

On April 1, 2019, the Company’s board of directors adopted the Sativus Tech Corp. 2018 Share Options Plan (the “2018 Plan”).

 

Awards granted under the 2018 Plan are subject to vesting schedules and unless determined otherwise by the administrator of the 2018 Plan, generally vest following a period of four years from the applicable vesting commencement date, such that the awards vest in four annual equal instalments and/or generally vest following a period of one year from the applicable vesting commencement date, such that the awards vest in four quarterly equal instalments.

 

 

 20 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 5: SHAREHOLDERS’ DEFICIT (cont.)

 

(i) A summary of employee share options activity during the nine months ended September 30, 2026, and the year ended December 31, 2025 is as follows:

        
   Number   Average weighted exercise price 
Options outstanding at January 1, 2025   65,000   $1.12 
Exercised   (65,000)   1.12 
           
Options outstanding at December 31, 2025   –    – 
Exercised   –    – 
           
Options outstanding at September 30, 2026   –   $– 

 

There were no options outstanding as of September 30, 2026 and December 31, 2025.

 

  d. Restricted Share Units:
     
    RSUs under the 2018 Plan may be granted upon such terms and conditions, no monetary payment (other than payments made for applicable taxes) shall be required as a condition of receiving the Company’s shares pursuant to a grant of RSUs, and unless determined otherwise by the Company, the aggregate nominal value of such RSUs shall not be paid and the Company shall capitalize applicable profits or take any other action to ensure that it meets any requirement of applicable laws regarding issuance of shares for consideration that is lower than the nominal value of such shares. If, however, the Company’s board of directors determines that the nominal value of the shares shall not be waived and shall be paid by the grantees, then it shall determine procedures for payment of such nominal value by the grantees or for collection of such amount from the grantees by the Company.

 

 

 21 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 5: SHAREHOLDERS’ DEFICIT (cont.)

 

   

Shares issued pursuant to any RSUs units may (but need not) be made subject to exercise conditions, as shall be established by the Company and set forth in the applicable notice of grant evidencing such award. During any restriction period in which shares acquired pursuant to an award of RSUs remain subject to exercise conditions, such shares may not be sold, exchanged, transferred, pledged, assigned or otherwise disposed of unless otherwise provided in the 2018 Plan. Upon request by the Company, each grantee shall execute any agreement evidencing such transfer restrictions prior to the receipt of shares hereunder and the Company may place appropriate legends evidencing any such transfer restrictions on the relevant share certificates.

 

A summary of RSU activity during the nine months ended September 30, 2026, and the year ended December 31, 2025 is as follows:

 

  Number 
     
RSU outstanding at January 1, 2025   531,000 
Granted   – 
Forfeited   – 
      
RSUs outstanding at December 31, 2025   531,000 
Forfeited   – 
      
RSUs outstanding at September 30, 2026   531,000 

 

 

 

 

 22 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 6: FINANCIAL INCOME (EXPENSES)

 

                
   Three months ended   Nine months ended 
   September 30,
2026
   September 30,
2025
   September 30,
2026
   September 30,
2025
 
                 
Financial income (expenses) related to revaluation component in convertible loans  $(185)  $(69)  $(157)  $(80)
Foreign currency transactions and other   6    (14)   (10)   (50)
   $(179)  $(83)  $(167)  $(130)

 

 

NOTE 7: LIENS, COMMITMENTS

 

  a. Saffron leases its facilities on leases that expired on December 15, 2024. Lease payments are approximately $5 per month ($60 annually). Saffron has the option to extend the lease period for two additional option periods of 12 months each (first option from December 16, 2024 to December 15, 2025 and second option from December 16, 2025 to December 15, 2026). Saffron did not extend the lease for a set amount of time but rather pays for each month it uses the facilities.
     
  b. Saffron Tech is committed to pay royalties to the IIA on the proceeds from sales of products resulting from research and development projects in which the IIA participates by way of grants. In the first 3 years of sales the Company shall pay 3% of the sales of the product which was developed under IIA research and development projects. In the fourth, fifth and sixth years of sales, the Company shall pay 4% of such sales and from the seventh year onwards the Company shall pay 5% of up to 100% of the amount of grants received plus interest at LIBOR. Saffron Tech was entitled to the grants only upon incurring research and development expenditures. There were no future performance obligations related to the grants received from the IIA. As of September 30, 2026, the contingent liabilities with respect to grants received from the IIA, subject to repayment under these royalty agreements on future sales is $Nil. As of September 30, 2026, Saffron Tech received a total of $223 (NIS 756 thousand) from the IIA.
     
  c. The Company’s holdings in Saffron Tech are secured to a third party until such time that the third-party convertible loans have been extinguished.

 

 

 

 23 

 

 

SATIVUS TECH CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
U.S. dollars in thousands

 

 

NOTE 7: LIENS, COMMITMENTS (cont.)

 

  d.

On September 29, 2025, Saffron Tech entered into a Memorandum of Understanding (the “BioHarvest MoU”) with BioHarvest Ltd. (“BioHarvest”), an Israeli biotechnology company, for the joint development of saffron cell culture-based compositions using BioHarvest’s plant cell culture technology. Development costs are shared 75% by Saffron Tech and 25% by BioHarvest. The development is structured in phases. Saffron Tech’s share of the costs is $375 for Phase I, $750 for Phase II and $750 for Phase III.

 

Saffron Tech may, at its sole discretion, elect to proceed to Phase III. The collaboration is exclusive with respect to Phase I and Phase II. If Phase I and Phase II are successfully completed under the agreed success criteria, the parties will establish a new entity, to be owned 75% by Saffron Tech and 25% by BioHarvest, which will own the developed compositions and the related intellectual property. The BioHarvest MoU has a term of three years.

 

Pursuant to an addendum dated November 10, 2025, all amounts under the BioHarvest MoU are exclusive of value added tax (“VAT”). Upon signing, Saffron Tech made an initial payment of $100 (including VAT), of which $85 (net of VAT) was recognized as research and development expenses during the year ended December 31, 2025.

 

The remaining payments under the BioHarvest MoU, consisting of the balance of approximately $290 for Phase I, up to $750 for Phase II and up to $750 for Phase III (all net of VAT), are contingent upon BioHarvest’s performance of the related development services. Research and development costs under the BioHarvest MoU are expensed as the related services are performed. As of September 30, 2026, no additional development services had been performed under the BioHarvest MoU, and accordingly no liability was recognized in respect of these amounts.

 

 

NOTE 8: SUBSEQUENT EVENTS

 

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no such events that warrant disclosure or recognition in the financial statements.

 

 

 

 24 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH OUR UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND THE RELATED NOTES THAT APPEAR ELSEWHERE IN THIS QUARTERLY REPORT ON FORM 10-Q AND THE FINANCIAL STATEMENTS AND RELATED NOTES THERETO FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 AND THE RELATED MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, BOTH OF WHICH ARE CONTAINED IN OUR ANNUAL REPORT ON FORM 10-K FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), ON APRIL 15, 2026. PAST OPERATING RESULTS ARE NOT NECESSARILY INDICATIVE OF RESULTS THAT MAY OCCUR IN FUTURE PERIODS. THE FOLLOWING DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT REFLECT OUR PLANS, ESTIMATES AND BELIEFS. OUR ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE THOSE DISCUSSED BELOW AND ELSEWHERE IN THIS QUARTERLY REPORT.

 

FORWARD-LOOKING STATEMENTS

 

This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. Forward-looking statements may include statements regarding our goals, beliefs, strategies, objectives, plans, including product and technology developments, future financial conditions, results or projections or current expectations. These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our actual results may differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this report, and we assume no obligation to update these forward-looking statements whether as a result of new information, future events, or otherwise, other than as required by law. In light of these assumptions, risks, and uncertainties, the forward-looking events discussed in this report might not occur and actual results and events may vary significantly from those discussed in the forward-looking statements. Further information on potential factors that could affect our business is described under the heading “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Readers are also urged to carefully review and consider the various disclosures we have made in that report.

 

When used in this quarterly report, the terms “Sativus,” “the Company,” “we,” “our,” and “us” refer to SATIVUS TECH CORP., a Delaware corporation, unless otherwise indicated or as otherwise required by the context.

 

 

 

 25 

 

 

Company Overview

 

SATIVUS TECH CORP. (formerly SEEDO CORP.) (the “Company”, “Our” or “We”) was formed on January 16, 2015, under the laws of the State of Delaware. Prior to July 2020, we were involved in producing a plant growing device managed and controlled by an artificial intelligence algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant, while providing optimal conditions to assure premium quality produce year-round. However, due to financial and operational difficulties and during 2020, we ceased these operations and on July 19, 2020, the Company formed a new wholly-owned subsidiary in Israel, Hachevra Legiduley Pkaot Beisrael Ltd. (the “New Subsidiary”), to develop a fully automated and remotely managed system for growing saffron and other vegetables. On November 5, 2020, the New Subsidiary changed its name to Saffron-Tech Ltd. (or “Saffron Tech”). As of the date of this report, and following various financings in Saffron Tech, the Company owns 54% of Saffron Tech.

 

The Company, through Saffron Tech, is focusing on its in-house research and development of agriculture technology products, among others, in the fields of exotic plants and mushrooms. Saffron Tech plans to roll out its proof of concept in the coming months. This technology will provide turnkey automated growing containers for high-quality, high-yield saffron all year round. The Company is in advanced stages of developing and testing a fully automated and remotely managed system for growing high-quality, high-yield saffron anywhere and anytime.

 

It is also environmentally friendly, using economic levels of water, space, fertilizer, and energy. According to the Company’s calculations, we believe that the controlled indoor growing area will produce ten times more yield compared to the same land area using traditional methods. The sealed environment eliminates the need for harmful pesticides and herbicides, producing a clean and safe product that is easy to control from anywhere. The Company’s solution is easily scalable and pre-designed to quickly grow operations.

 

Saffron is used in many industries, such as the food industry, particularly by famous chefs and Michelin starred restaurants, the natural cosmetics industry and the food supplements industry and as a dye in the textile industry. Medicinal claims as an anti-depressant, antioxidant, and antiseptic are constantly increasing.  

On January 6, 2022, the Company announced that its subsidiary, Saffron Tech, has planted approximately 25,000 Saffron bulbs in fields in the Golan Heights, in Northern Israel. The plantation is being managed in conjunction with the Shamir Research Institute.

 

On April 4, 2022, the Company announced that Mr. Moshe Bar Siman Tov and Mrs. Iris Tova Ginsburg have resigned from the Board of Directors of the Company, and immediately appointed Mrs. Tal Wilk-Glazer to its Board of Directors and as CEO of the Company.

 

In April 2022, Saffron Tech announced its new state-of-the-art indoor research and development center is operational. From April 2022, through to December 2022, Saffron Tech successfully completed three Saffron cultivation cycles using vertical farming technology, while traditional agriculture only produces one harvest of saffron per year.

 

On August 30, 2022, Saffron Tech, announced its intention to raise up to 5 million New Israeli Shekels (“NIS”) (approximately $1.5 million) at a pre-money valuation of NIS 32.5 million (approximately $10 million) through the Israeli crowdfunding platform – Pipelbiz (“2022 Crowd Funding Round”). Assuming the maximum amount is raised, the Company will own approximately 61% of Saffron Tech. The 2022 Crowd Funding Round was closed on December 1, 2022, having raised 3.8 million NIS (approximately $1.3 million). Fundraising expenses accumulated to $152 and the net amount raised through Pipelbiz was $1.15 million. Saffron Tech also raised 1.15 million NIS (approximately $328 thousand) through the issuance of SAFEs. The SAFEs are convertible at a 20% discount to the current crowdfunding round. Sativus Tech’s interest in Saffron Tech now totals 67.5% post-raise. All SAFEs were converted before December 31, 2022. Saffron Tech continued to raise funds through Pipelbiz under the same pre-money valuation from December 2022 through to January 2023, via another crowdfunding round “2023 Crowd Funding Round” which closed on February 5, 2023, having raised another 1.1 million NIS (approximately $314 thousand).

 

 

 

 26 

 

 

On March 1, 2023, Saffron Tech entered into an investment agreement with Korean-based company, Dreamtech Co Ltd (“Dreamtech”), a leading provider and manufacturer of tech components for innovative products including advanced mobile and medical devices. Under this new agreement, Dreamtech will fund an initial investment of $1 million followed by an additional $1 million upon a successful cultivation of saffron in Korea. On March 5, 2023, Dreamtech officially announced a successful completion of the POC for Saffron cultivation in Korea, while meeting the defined success measurements for saffron quantity and saffron quality.

 

Saffron Tech aims to be the first company to create a large-scale production of saffron using vertical farming technology to meet the growing demand of the spice for use in beauty, wellness, and pharmaceutical applications. Sativus Tech’s interest in Saffron Tech now totals 54% post-raise.

 

On May 9, 2024, Saffron Tech launched a pilot site in Ganei Tal, Israel. The pilot demonstrates commercial-like Saffron cultivation, using Saffron Tech proprietary technology and growth protocol. In the pilot site Saffron Tech will grow more than 12,000 corms in parallel, 4 cycles a year. The company invested $290 thousand. The Israel Innovation Authority (“IIA”) participation was $250 thousand.

 

On October 28th, 2024, the Board appointed Board Member and Director Shmuel (Shmulik) Yannay as CEO of the Company. On the same day Tal Wilk-Glazer resigned her position as Director, CEO & Board Member. Her resignation was not the result of any dispute with the Company.

 

On October 20th, 2025, the Board appointed Board Member and Director Michael Oster as CEO of the Company. On the same day Shmulik Yannay resigned his position as Director, CEO & Board Member. His resignation was not the result of any dispute with the Company.

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited condensed financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

These unaudited condensed financial statements should be read in conjunction with our December 31, 2025, annual financial statements included in our Form 10-K, filed with the SEC on April 15th, 2026.

 

Going Concern

 

Due to the uncertainty of our ability to meet our current operating and capital expenses, our independent auditors included an explanatory paragraph in their report on our consolidated financial statements for the year ended December 31, 2025, regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that led to this disclosure by our independent auditors.

 

 

 

 27 

 

 

Our unaudited condensed financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our unaudited condensed financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. There is no assurance that our operations will be profitable. Our continued existence and plans for future growth depend on our ability to obtain the additional capital necessary to operate either through the generation of revenue or the issuance of additional debt or equity.

 

Financing

 

We will require additional financing to implement our business plan, which may include joint venture projects and debt or equity financings. The nature of this enterprise and constraint of positive cash flow places debt financing beyond the credit-worthiness required by most banks or typical investors of corporate debt until economically viable operations can be demonstrated. Therefore, any debt financing of our activities may be costly and result in substantial dilution to our stockholders.

 

Future financing through equity investments is likely to be dilutive to existing stockholders. Also, the terms of securities we may issue in future capital transactions may be more favorable for our new investors. Newly issued securities may include preferences, superior voting rights, and the issuance of warrants or other derivative securities, which may have additional dilutive effects. Further, we may incur substantial costs in pursuing future capital and financing, including investment banking fees, legal fees, accounting fees, and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we may issue, such as convertible notes and warrants, which will adversely impact our financial condition.

 

Our ability to obtain needed financing may be impaired by such factors as the capital markets, both generally and specifically in the Agro-tech industry, which could impact the availability or cost of future financings. If the amount of capital we are able to raise from financing activities, together with our revenue from operations, is not sufficient to satisfy our capital needs, even to the extent that we reduce our operations accordingly, we may be required to cease operations.

 

There is no assurance that we will be able to obtain financing on terms satisfactory to us, or at all. We do not have any arrangements in place for any future financing. If we are unable to secure additional funding, we may cease or suspend operations. We have no plans, arrangements or contingencies in place in the event that we cease operations.

 

Results of Operations

 

Nine months ended September 30, 2026 compared to the nine months ended September 30, 2025

 

Operating Expenses

 

Research and development expenses for the nine months ended September 30, 2026, were $187 thousand compared to $497 thousand for the same period in 2025. The decrease of $310 thousand was mainly due to a decrease of $191 thousand in salaries and related expenses, as no research and development salary expenses were incurred in the third quarter of 2026, a decrease of $37 thousand in rent expenses, a decrease of $28 thousand in depreciation expenses and a decrease of $54 thousand in other expenses.

 

 

 

 28 

 

 

General and administrative (“G&A”) expenses for the nine months ended September 30, 2026, were $185 thousand compared to $296 thousand for the same period in 2025. The decrease of $111 thousand was mainly due to a decrease in professional services.

 

Total financial income (expenses), net for the nine months ended September 30, 2026, was $167 thousand expense compared to $130 thousand expense for the same period in 2025. Financial expenses and income are due to financial expenses and income related to revaluations of the convertible component in convertible loans.

 

Three months ended September 30, 2026 compared to the three months ended September 30, 2025

 

Operating Expenses

 

Research and development expenses for the three months ended September 30, 2026, were $15 thousand compared to $169 thousand for the same period in 2025. The decrease was mainly due to the absence of research and development salary expenses in the third quarter of 2026.

 

General and administrative (“G&A”) expenses for the three months ended September 30, 2026, were $51 thousand compared to $151 thousand for the same period in 2025. The decrease was mainly due to lower professional services fees.

 

Total financial income (expenses), net for the three months ended September 30, 2026, was $179 thousand expense compared to $83 thousand expense for the same period in 2025. Financial expenses and income are due to financial expenses and income related to revaluations of the convertible component in convertible loans.

 

Liquidity and Capital Resources

 

Overview

 

Since inception on January 16, 2015, the Company has a cumulative deficit of $24,881 thousand and a working capital deficit of $4,014 thousand as of September 30, 2026. Our future growth is dependent upon achieving further purchase orders and execution, management of operating expenses and ability of the Company to obtain the necessary financing to fund future obligations, and upon profitable operations. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.

 

Historically, we have financed our cash flow and operations from the initial contribution of our majority shareholder and by raising equity and convertible loans and warrants.

 

We had a negative working capital of $4,014 thousand and $3,735 thousand as of September 30, 2026, and December 31, 2025, respectively.

 

 

 

 29 

 

 

During the nine months ended September 30, 2026, we had negative cash flow from operations of $237 thousand which was mainly the result of a net loss of $539 thousand, offset by changes in assets and liabilities of $85 thousand, depreciation of $60 thousand, financial expenses related to convertible loans and warrants of $126 thousand and financial expenses from revaluations of convertible component in convertible loans in the amount of $31 thousand. Cash flow from operation activity in the nine months ended September 30, 2025, was the result of a net loss of $923 thousand, and financial gains from revaluations of convertible component in convertible loans in the amount of $48 thousand offset by changes in assets and liabilities of $273 thousand, depreciation of $89 thousand, and financial expenses related to convertible loans and warrants of $127 thousand.

 

During the nine months ended September 30, 2026, we had negative cash flow from investing activities of $1 thousand compared to a positive cash flow of $5 thousand for the same period in 2025. The negative investing cash flow was the result of an increase in restricted cash of $1 thousand.

 

During the nine months ended September 30, 2026, we had positive cash flow from financing activities of $224 thousand compared to a positive cash flow from financing activities during the nine months ended September 30, 2025 of $540 thousand. The positive financing cash flow during the nine months ended September 30, 2026 was primarily the result of proceeds from SAFE agreements in subsidiary and an increase in loans from a related party of $24 thousand. The positive financing cash flow during the nine months ended September 30, 2025 was primarily the result of proceeds from a convertible loan and from issuance of shares to minority interests in subsidiary.

 

On September 29, 2025, Saffron Tech entered into a Memorandum of Understanding with BioHarvest Ltd. for the joint development of saffron cell culture-based compositions. Saffron Tech’s share of the development costs is up to $1,875 thousand, of which $100 thousand (including VAT) was paid in 2025. The remaining payments are contingent upon BioHarvest’s performance of the related development services, and no liability was recognized as of September 30, 2026. Any such payments will require additional financing. See Note 7d to the condensed consolidated financial statements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”) and are not required to provide the information required under this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

In connection with the preparation of our Quarterly Report on Form 10-Q, an evaluation was carried out by management, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

 

 

 30 

 

 

During evaluation of disclosure controls and procedures as of September 30, 2026, conducted as part of our preparation of the quarterly unaudited condensed financial statements, management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures and concluded that our disclosure controls and procedures were not effective.

 

Changes in Internal Control Over Financial Reporting

 

During the quarter ended September 30, 2026, there have been no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

 

 

 

 

 31 

 

 

Part II - Other Information

 

Item 5. Other Information

 

During the quarter ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

Item 6. Exhibits

 

Exhibit
Number
  Description
10.1   Form of Subscription Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 2, 2019).
31.1*   Rule 13a-14(a) Certification of the Chief Executive Officer
31.2*   Rule 13a-14(a) Certification of the Chief Financial Officer
32.1**   Section 1350 Certification of Chief Executive Officer
32.2**   Section 1350 Certification of Chief Financial Officer
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.
** Furnished herewith.

 

 

 

 32 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated.

 

Dated: November 16, 2026 By: /s/ Michael Oster
    Michael Oster
    Chief Executive Officer
    SATIVUS TECH CORP.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 33